jie chen

Dr. jie chen

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2023 in Journal of Autoimmunity
Verified
Journal Article
Open access
LLLiyan Lin
Liyan Lin
KZKeyi Zhang
Keyi Zhang
QXQiao Xiong
Qiao Xiong
JZJunlong Zhang
Junlong Zhang
BCBei Cai
Bei Cai
QNQian Niu
Qian Niu
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive polyarthritis that leads to cartilage and bone damage. Pre-clinical RA is a prolonged state before clinical arthritis and RA develop, in which autoantibodies (antibodies against citrullinated proteins, rheumatoid factors) can be present due to the breakdown of immunologic self-tolerance. As early treatment initiation before the onset of polyarthritis may achieve sustained remission, optimize clinical outcomes, and even prevent RA progression, the pre-clinical RA stage is showing the prospect to be the window of opportunity for RA treatment. Growing evidence has shown the role of the gut microbiota in inducing systemic inflammation and polyarthritis via multiple mechanisms, which may involve molecular mimicry, impaired intestinal barrier function, gut microbiota-derived metabolites mediated immune regulation, modulation of the gut microbiota's effect on immune cells, intestinal epithelial cells autophagy, and the interaction between the microbiome and human leukocyte antigen alleles as well as microRNAs. Since gut microbiota alterations in pre-clinical RA have been reported, potential therapies for modifying the gut microbiota in pre-clinical RA, including natural products, antibiotic therapy, fecal microbiota transplantation, probiotics, microRNAs therapy, vitamin D supplementation, autophagy inducer-based treatment, prebiotics, and diet, holds great promise for the successful treatment and even prevention of RA via altering ongoing inflammation. In this review, we summarized current studies that include pathogenesis of gut microbiota in RA progression and promising therapeutic strategies to provide novel ideas for the management of pre-clinical RA and possibly preventing arthritis progression.

4 November 2022 in Journal of Materials Chemistry A
Verified
Journal Article
Closed access
PDF file
HWHaipeng Wang
Haipeng Wang
DZDonglin Zhao
Donglin Zhao
CLChaozhen Liu
Chaozhen Liu
XFXiaoya Fan
Xiaoya Fan
ZLZerong Li
Zerong Li
Xuping SunXuping Sun
Xuping Sun
FeS2@TiO2 is a highly active electrocatalyst for the conversion of NO3− to NH3 under ambient conditions, achieving a high faradaic efficiency of 97.0% at −0.4 V and a large NH3 yield up to 860.3 μmol h−1 cm−2 at −0.7 V in 0.1 M NaOH with 0.1 M NO3−.

21 October 2022 in Journal of Materials Chemistry A
Verified
Journal Article
Closed access
PDF file
LOLing Ouyang
Ling Ouyang
He XunHe Xun
He Xun
SSShengjun Sun
Shengjun Sun
YLYongsong Luo
Yongsong Luo
DZDongdong Zheng
Dongdong Zheng
Xuping SunXuping Sun
Xuping Sun
P-doped TiO2 nanobelt array supported on titanium plate acts as a high efficiency electrocatalyst for NO2− reduction reaction, attaining a satisfactory faradaic efficiency of 90.6% and a large NH3 yield as high as 560.8 μmol h−1 cm−2.

11 November 2022 in Journal of Materials Chemistry A
Verified
Journal Article
Closed access
PDF file
HQHang Qiu
Hang Qiu
QCQiuyue Chen
Qiuyue Chen
XAXuguang An
Xuguang An
QLQian Liu
Qian Liu
LXLisi Xie
Lisi Xie
Xuping SunXuping Sun
Xuping Sun
Monoclinic WO2 nanoparticles with oxygen vacancies are efficient for electrochemical NO2− reduction to NH3, offering an NH3 yield rate of 14 964.25 ± 826.06 μg h−1 cm−2 and a faradaic efficiency of 94.32 ± 1.15%.

17 January 2022 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
PCPiaopiao Chen
Piaopiao Chen
YHYaqin He
Yaqin He
TLTangyuheng Liu
Tangyuheng Liu
FLFengling Li
Fengling Li
KHKe Huang
Ke Huang
BYBinwu Ying
Binwu Ying

23 February 2023 in European Journal of Cancer
Verified
Journal Article
Open access
ZXZhaodan Xin
Zhaodan Xin
LYLiting You
Liting You
FNFeifei Na
Feifei Na
JLJin Li
Jin Li
MCMin Chen
Min Chen
BYBinwu Ying
Binwu Ying
PD-1/PD-L1 inhibitors have brought remarkable benefits but can cause profound immune-related adverse events (irAEs). The host immunogenetic background is likely to play a role in irAE susceptibility. In this study, we aimed to identify potential immunogenetic biomarkers to predict irAEs. Patients with solid tumours receiving PD-1/PD-L1 blockade were recruited and followed up. Genes considered pivotal contributors to tumour-immunity and autoimmune diseases were screened out via protein-protein interaction network and Cytoscape. Consequently, thirty-nine variants in eighteen genes were genotyped using the multiplex genotyping assay. Association analysis between genetic variants and irAEs as well as irAEs-free survival was performed. Four immunogenetic variants as predictive biomarkers of irAEs were identified. The C allele of Mitogen-Activated Protein Kinase 1 (MAPK1) rs3810610 (odds ratio [OR] = 1.495, 95% confidence interval [CI] = 1.093-2.044, P = 0.012) was a risk predictor while the A allele of PTPRC rs6428474 (OR = 0.717, 95% CI = 0.521-0.987, P = 0.041) was a protective factor for all-grade irAEs. The A allele of ADAD1 rs17388568 (OR = 2.599, 95% CI = 1.355-4.983, P = 0.003) increased the risk while the G allele of IL6 rs1800796 (OR = 0.425, 95% CI = 0.205-0.881, P = 0.018) protected patients from high-grade irAEs. Significant immunogenetic variants reached a similar tendency in PD-1 blockade or lung cancer subgroups. In multivariate Cox regression analysis, the MAPK1 rs3810610 was an independent factor regarding all-grade irAEs-free survival (CC versus CT or TT: hazard ratio [HR] = 0.71, 95% CI = 0.52-0.99, P = 0.042). ADAD1 rs17388568 (AA versus AG or GG: HR = 0.11, 95% CI = 0.025-0.49, P = 0.004) and IL6 rs1800796 (GG or GC versus CC: HR = 3.10, 95% CI = 1.315-7.29, P = 0.01) were independent variables for high-grade irAEs-free survival. We first identified several immunogenetic polymorphisms associated with irAEs and irAEs-free survival in PD-1/PD-L1 blockade-treated tumour patients, and they may serve as potential predictive biomarkers.